Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 28

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Gastric cancer+1

Recruiting

Study of Avelumab with Chemotherapy for Patients with Resectable Stomach or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Oesophageal adenocarcinoma

Recruiting

Study on Adding Trastuzumab and Pertuzumab to Treatment for Patients with Resectable HER2 Positive Esophageal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Amsterdam UMC Stichting

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Gastrooesophageal reflux disease+1

Recruiting

Study on Omeprazole and Cow's Milk-Free Diet for Treating Gastroesophageal Reflux Disease in Infants Under 1 Year

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Omeprazole
  • Sponsor:Odense University Hospital

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine Besilate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Pancreatic failure

Recruiting

Study on Pancreatic Enzyme Replacement Therapy for Adults with Pancreatic Exocrine Insufficiency After Pancreatic Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pancreas Powder
  • Sponsor:MEDA Pharma GmbH & Co. KG

Inguinal hernia

Recruiting

Study on the Effect of Ropivacaine Hydrochloride and Sodium Chloride on Recovery After Inguinal Hernia Surgery for Patients Undergoing Open Surgery

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Pirkanmaan hyvinvointialue

Colorectal cancer

Recruiting

Study on the Effects of Aspirin and Omeprazole in Obese and Non-Obese Patients with Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria Aragon

Colon cancer metastatic

Recruiting

Study Comparing Dostarlimab with CAPEOX and CAPEOX Alone for Patients with Untreated Stage III Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of Oxaliplatin or Gemcitabine Chemotherapy in Patients with Resected Pancreatic Cancer Using Standard or Genetic Allocation Methods

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Colorectal cancer metastatic

Recruiting

Study of Pembrolizumab, Dendritic Cell Vaccine, Trifluridine/Tipiracil, and Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Endometrial cancer+3

Recruiting

Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.